§1028.1. Required coverage for breast and ovarian cancer susceptibility screening
A. The legislature hereby finds that a woman's lifetime risk of developing breast or
ovarian cancer is greatly increased if she inherits a harmful mutation in the BRCA1 or
BRCA2 genes. Testing for the presence of BRCA1 or BRCA2 gene mutations may allow
for interventions to reduce the risk for cancer or cancer-related death in women who are
BRCA mutation carriers.
B.(1) Any health coverage plan delivered or issued for delivery in this state shall
include coverage for the cost of the genetic testing of the BRCA1 and BRCA2 genes to
detect an increased risk for breast and ovarian cancer when recommended by a healthcare
provider in accordance with the United States Preventive Services Task Force
recommendations for testing.
(2) The coverage provided in this Section may be subject to annual deductibles,
coinsurance, and copayment provisions as are consistent with those established under the
health coverage plan.
C. For purposes of this Section, "health coverage plan" means any hospital, health,
or medical expense insurance policy, hospital or medical service contract, employee welfare
benefit plan, contract, or other agreement with a health maintenance organization or a
preferred provider organization, health and accident insurance policy, or any other insurance
contract of this type in this state, including a group insurance plan, a self-insurance plan, and
the Office of Group Benefits programs. "Health coverage plan" shall not include a plan
providing coverage for excepted benefits as defined in R.S. 22:1061, limited benefit health
insurance plans, and short-term policies that have a term of less than twelve months.
Acts 2019, No. 118, §1, eff. Jan. 1, 2020.